In this article
Hims & Hers
on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and threats of legal action earlier this week.
“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” the telehealth provider posted on social media. “As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.”
Hims & Hers had previously said it planned to create a cheaper, copycat version of pharmaceutical giant Novo Nordisk’s
